Previously, we also demonstrated a reduction in CD83 expression when monocyte derived DCs were cultured in Bevacizumab conditioned media (ex vivo CRC tumor tissue was cultured in media +/− Bevacizumab) and this inhibition of LPS-induced CD83, expression significantly correlated with poorer clinical outcome [56]. The gene discussed is CD83; the disease is colorectal carcinoma.